GMH*
11 minutes ago
Since the markets are closed, here is a good discussion on Amtagvi by the the University of Kansas - Cancer Center. First 40 minutes is oncologist discussing TIL (this is a repeat of a lot of other presentations), but starting at 40 minutes, you get the surgeon's view which is quite interesting...